Early DAA treatment cost-effective for kids with HCV
In children with hepatitis C virus (HCV) infection, early treatment with direct-acting antivirals (DAA) is a more cost-effective option than delaying to adulthood, leading to averted cases of cirrhosis, malignancies, and deaths, a new study has found.